Vivacelle Bio Commemorates Sepsis Awareness Month, Recognizing the Leading Cause of Death in U.S. Hospitals
Recent News
Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S
Vivacelle Bio Commemorates Sepsis Awareness Month, Recognizing the Leading Cause of Death in U.S. Hospitals
Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S
Surge in Septic Shock Care: Vivacelle’s Innovative Approach
Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock
Vivacelle Bio's President and Chief Innovation Officer to Present Data Highlighting the Company's Late-Stage Clinical Programs at the BIO International Convention 2024
Sepsis is to blame for the 40-year-old mother's unexpected death. It sheds light on broader maternal healthcare issues for Black women.
Vivacelle Bio and University of Missouri-Kansas City School of Medicine Announce Groundbreaking Results from Phase 2a Clinical Trial of VBI-S for Refractory Hypotension in Severe Septic Shock Patients
Vivacelle Bio Integrates Sub-Saharan Africa Strategy into Series B Financing Round
Feds hope to cut sepsis deaths by hitching Medicare payments to treatment stats
The Lancet Journal - Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2
Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients
Septic Shock Market is Expected to Expand at a Healthy Growth Rate by (2022-2032), States DelveInsight | Key Companies – Adrenomed AG, Vivacelle Bio, Inotrem
Sepsis And Septic Shock Treatment Market Hitting New Highs By 2028 | VBI-S: Vivacelle Bio, Nangibotide (LR12): Inotrem, Allocetra: Enlivex Therapeutics
Vivacelle Bio named included in 101 top Illinois Biotechnology Companies and Startups - 2021